Program
SHR-4712
A development code. Also written as “SHR-4712 Injection”.
Its studies are led by Jiangsu HengRui Medicine.
Furthest: phase 1, since May 19, 20251 company-led study, 1 open or runningNext primary completion: May 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 11 open or running | phase 1since May 19, 2025 | May 19, 2025 | May 2027phase 1 · NCT06993116 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-4712
, phase 1, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2025First study: phase 1 study in Advanced Solid TumorFirst studyNCT06993116 · 15 enrolled · China
Ahead
- May 2027Primary completion: phase 1 study in Advanced Solid TumorNCT06993116
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06993116Advanced Solid Tumor · China | 1 | Active, not recruiting | May 2027 | 15 |
How it is read
Names in the registry
- “SHR-4712 Injection”, 1 entry
Codes read as this program: SHR4712.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.